Due to the COVID-19 pandemic, the global Ropivacaine Mesylate for Injection market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Ropivacaine Mesylate for Injection market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Ropivacaine Mesylate for Injection landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
10ml/Piece accounting for % of the Ropivacaine Mesylate for Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Ropivacaine Mesylate for Injection include Shanxi PUDE Pharmaceutical, Cisen Pharmaceutical, Hainan Star Pharmaceutical, Anhui Weiman Pharmaceutical, Yangtze River Pharmaceutical, Zhejiang Hailisheng Pharmaceutical, Jiangsu Nhwa Pharmaceutical, Xi`an Han Feng Pharmaceutical and Shandong New Time Pharmaceutical. etc. In terms of revenue, the global 3 largest players have a % market share of Ropivacaine Mesylate for Injection in 2021.
This report focuses on Ropivacaine Mesylate for Injection volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Ropivacaine Mesylate for Injection market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: China., etc.
Global Ropivacaine Mesylate for Injection Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Specification and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Specification
10ml/Piece
20ml/Piece
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Shanxi PUDE Pharmaceutical
Cisen Pharmaceutical
Hainan Star Pharmaceutical
Anhui Weiman Pharmaceutical
Yangtze River Pharmaceutical
Zhejiang Hailisheng Pharmaceutical
Jiangsu Nhwa Pharmaceutical
Xi`an Han Feng Pharmaceutical
Shandong New Time Pharmaceutical